Recent developments include Zimmer Biomet’s Q1 2026 earnings and revenues surpassing prior periods, a rise in quarterly profit, and a CFO transition. The company continues to implement its 2025 global restructuring plan aimed at cost reduction and operational transformation.

• Zimmer Biomet reported Q1 2026 earnings and revenues with net sales reaching approximately $2.09 billion and net income of $238.1 million, reflecting profit growth compared to prior periods [N1][N2][N3][N4].
• The company held its Q1 2026 earnings conference call on April 28, 2026, discussing key metrics and operational highlights [N5].
• Zimmer Biomet’s CFO Suketu Upadhyay stepped down on April 28, 2026, with Paul Stellato appointed as interim CFO [N6].
• Q1 2026 profit climbed compared to previous periods, indicating improved profitability [N7].
• The company’s Q4 2024 earnings transcript provides additional context on prior performance and strategic positioning [N8].

Zimmer Biomet’s extensive product portfolio across multiple orthopedic and surgical categories provides a diversified revenue base. The company’s global restructuring plan targets significant cost reductions and operational transformation, which may improve profitability and efficiency. Strong liquidity metrics and a robust cybersecurity program support operational stability. Recent earnings reports indicate growth in sales and profitability, and leadership changes may bring fresh strategic perspectives. The company’s geographic diversification and established market presence underpin its ability to serve a broad customer base.

Zimmer Biomet faces risks related to its substantial long-term debt and the execution of its global restructuring plan, which involves employee terminations and contract terminations that could disrupt operations. The narrow margin of fair value over carrying value in certain reporting units suggests potential impairment risks. Leadership transitions, including the CFO stepping down, may introduce short-term uncertainty. The medical device industry is competitive and subject to regulatory and reimbursement pressures. Cybersecurity threats remain a risk despite robust governance. Cost reduction initiatives may not fully offset operational challenges or market fluctuations.

Zimmer Biomet’s moat is supported by its diversified and broad product portfolio in the medical device sector, including established product categories such as knees, hips, and sports medicine. The company’s global footprint and geographic diversification provide resilience and market reach. Its ongoing restructuring efforts aim to enhance operational efficiency and cost competitiveness. The company’s investment in cybersecurity and governance reflects a commitment to protecting its operations and intellectual property. Additionally, Zimmer Biomet’s scale and integration of acquisitions contribute to its competitive positioning in the medical device market.

• Execution Risk of Restructuring Plan: The 2025 Restructuring Plan involves significant cost reduction initiatives including employee terminations and contract terminations, which may disrupt operations or affect employee morale.
• Financial Leverage: Zimmer Biomet carries substantial long-term debt (approximately $6.3 billion as of March 31, 2026), which may impact financial flexibility and increase interest expense.
• Cybersecurity Risks: Despite a comprehensive cybersecurity program, the company remains exposed to potential cybersecurity incidents that could affect financial results, operations, or reputation.
• Leadership Transition: The recent stepping down of the CFO and appointment of an interim CFO may introduce short-term management uncertainty.
• Market and Regulatory Environment: The medical device industry is subject to competitive pressures, regulatory changes, and reimbursement challenges that could impact sales and profitability.

• Zimmer Biomet Holdings, Inc. is a medical device company with a product portfolio including knees, hips, S.E.T. (Sports Medicine, Extremities, Trauma, Craniomaxillofacial and Thoracic), and Technology & Data, Bone Cement and Surgical products.
• For the three months ended March 31, 2026, Zimmer Biomet reported net sales of approximately $2.09 billion, with $1.21 billion from the United States and $877 million internationally.
• Net sales by product category for Q1 2026 included Knees at $793 million, Hips at $524 million, S.E.T. at $562 million, and Technology & Data, Bone Cement and Surgical at $172 million.
• The company reported a net income of $238.1 million for Q1 2026, with basic and diluted earnings per share of $1.22.
• Operating profit for Q1 2026 was $373.2 million, with operating expenses totaling $1.71 billion.
• Zimmer Biomet has a global restructuring program approved in 2025, targeting cost reductions and operational transformation, with expected pre-tax restructuring charges of approximately $155 million by the end of 2027.
• As of March 31, 2026, Zimmer Biomet had cash and cash equivalents of $424.2 million and current assets of $4.96 billion, against current liabilities of $2.86 billion, resulting in a current ratio of 1.73 and a cash ratio of 0.16.
• The company’s long-term debt as of March 31, 2026, was approximately $6.3 billion, with total liabilities around $10 billion and total assets of about $22.7 billion.
• Zimmer Biomet’s cybersecurity program is overseen by the Audit Committee and led by a Chief Information Security Officer with over 30 years of experience, with established processes for incident review and disclosure.
• Recent leadership changes include the stepping down of CFO Suketu Upadhyay and appointment of Paul Stellato as interim CFO as of April 28, 2026.
• The company’s Q1 2026 earnings and revenues topped estimates, with profit climbing compared to prior periods.
• Zimmer Biomet’s business segments are organized geographically and by product categories, with all product categories sold across all reportable operating segments.
• The company’s restructuring and cost reduction initiatives are reported under a specific financial statement line item and include employee termination benefits and contract terminations.
• Zimmer Biomet’s net sales have shown growth compared to prior periods, with increases in key product categories and geographic regions.
• The company’s financial disclosures are comprehensive and include detailed segment and geographic sales data, restructuring plans, and liquidity metrics.
• Zimmer Biomet’s liquidity position as of March 31, 2026, shows a strong current ratio of 1.73, indicating adequate short-term financial health.
• The company’s operating expenses include research and development, selling, general and administrative expenses, restructuring costs, and acquisition-related expenses.
• Zimmer Biomet’s net earnings attributable to the company were $238.1 million for Q1 2026, with a weighted average diluted share count of approximately 195.8 million shares.
• The company’s financial figures are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice.